FibroBiologics, Inc. Common Stock (FBLG) — Working Capital to Net Assets Ratio
FibroBiologics, Inc. Common Stock (FBLG) has a Working Capital to Net Assets ratio of -1185.6% as of September 2025. Working capital of $-1.48 Million (current assets of $5.24 Million minus current liabilities of $6.72 Million) is measured against net assets of $125.00K. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
FibroBiologics, Inc. Common Stock Working Capital to Net Assets (2022–2025)
This chart shows how FibroBiologics, Inc. Common Stock's Working Capital to Net Assets ratio has evolved across 4 annual periods from 2022 to 2025. As of September 2025, the ratio stands at -1185.6%, reflecting working capital of $-1.48 Million against net assets of $125.00K USD. See FBLG days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for FibroBiologics, Inc. Common Stock (2022–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for FibroBiologics, Inc. Common Stock from 2022 to 2025, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see FibroBiologics, Inc. Common Stock (FBLG) total assets.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 54.9% | $1.50 Million | $2.73 Million | $14.23 Million | $12.73 Million | ▲ +52.4 pp |
| 2024 | 2.6% | $32.00K | $1.25 Million | $9.21 Million | $9.18 Million | ▼ -108.8 pp |
| 2023 | 111.3% | $-4.45 Million | $-4.00 Million | $2.62 Million | $7.07 Million | ▲ +11.3 pp |
| 2022 | 100.0% | $-1.29 Million | $-1.29 Million | $468.00K | $1.76 Million | — |